Thymosin alpha1 based immunomodulatory therapy for XXXX : a systematic review and meta-analysis.

@entity1 @entity295
OBJECTIVES: Thymosin alpha1 (Ta1) is considered a promising immunomodulatory drug. However, it is still unclear whether Ta1 should be recommended for the management of @entity295 . Here we conducted a systematic review and meta-analysis to assess the efficacy of Ta1 based immunomodulatory therapy on the clinical outcomes of septic @entity1 . METHODS: We searched for relevant clinical trials published before Dec. 12, 2014 through electronic databases. All articles about Ta1 based immunomodulatory therapy for @entity295 were included regardless of language. Two authors independently selected studies, extracted data and assessed the quality of each included study. We polled the data related to all-cause mortality with Review Manager 5.1. RESULTS: Twelve controlled trials were evaluated in all. Ta1 based immunomodulatory therapy had a significant trend toward lower all-cause mortality among @entity1 with @entity295 (pooled risk ratio 0.68, 95%CI 0.59-0.78, p<0.00001, 12 trials, n=1480). CONCLUSIONS: Ta1 based immunomodulatory therapy was associated with a lower mortality in septic @entity1 . Nevertheless, these findings should be interpreted cautiously because of the poor quality and small number of @entity1 of the included trials. More well-designed worldwide multicenter clinical trials are needed to provide a conclusive guideline for clinical practice.
